Drug Profile

DSP 2342

Alternative Names: DSP-2342

Latest Information Update: 14 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sumitomo Pharma
Developer Recursion Pharmaceuticals; Sumitomo Pharma
Class Behavioural disorder therapies; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor antagonists; Serotonin 7 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Oct 2025 Phase-I development is ongoing in USA (https://www.sumitomo-pharma.com/rd/pipeline_new-medicine/pipeline.html)
20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals
15 May 2023 Exscientia and Sumitomo Pharm agree to co-promote and co-develop DSP 2342 in for Psychiatric disorders

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com